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Abstract  
 
Many options exist for the treatment of localized prostate cancer. In the decision to 
choose a therapeutic option for localized disease, many variables need to be considered such as 
tumor characteristics, clinical stage, the patient’s overall health and life expectancy, and 
preferences of both the physician and patient. Another important consideration is the health-
related quality of life (HRQOL) implications of a given treatment option. The importance of 
HRQOL relative to the potential side effects of prostate cancer treatments has grown over the 
past few years.  Although our collective awareness has increased, objective data on HRQOL for 
prostate cancer treatment are lacking due to a paucity of prospective clinical trial data. This 
review defines the concept of HRQOL, discusses what is currently known about the impact of 
various treatments on HRQOL, and summarizes the recent literature in this area relating to the 
management of localized prostate cancer. 
 
Keywords: prostate cancer, radical prostatectomy, external beam radiation therapy, 
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Introduction 
Prostate-specific antigen (PSA)-based screening for prostate cancer (CaP) has resulted in 
a stage migration, leading patients to be diagnosed earlier in the disease process, at a younger age 
and with lower risk factors [1, 2]. Data from the large Cancer of the Prostate Strategic Urologic 
Research Endeavor (CaPSURE) database demonstrated a significant increase in the proportion of 
patients with low-risk tumor characteristics from 29.8% in 1989–1992 to 45.3% in 1999–2001 
[2]. More importantly, the robust favorable long-term survival in low-risk CaP has become even 
more pronounced in recent years because PSA testing has led to cancer diagnosis at an earlier 
point of the disease course and to be alive longer with their disease. In fact, progression-free 
survival following local intervention for low-risk CaP approaches 95% at 10 years [3].  
Various established treatment options exist for clinically localized CaP, such as active 
surveillance (AS), radical prostatectomy (RP), radiotherapy (RT), and brachytherapy (BT). Some 
of these, such as radiation therapy, can include hormonal therapy in the regimen. Unfortunately, 
there have been no adequately sized randomized clinical trials to directly compare the various 
interventions for CaP, and past attempts to compare interventions such as brachytherapy and 
radical prostatectomy have not been successful. Therefore, in the setting in which one treatment 
option cannot be ruled superior to another, the side effect profiles of the different treatment 
options are often considered with making a treatment decision. Understanding the health related 
quality of life (HRQOL) enables the urologist and individual patient to have realistic 
expectations and to optimize treatment decisions for the CaP patient. Customizing risk profile to 
each patient can also prove to be important, such as taking into consideration the patient’s 
baseline health, anxiety, and expectations. For example, a patient who has a history of 
obstructive urinary symptoms related to symptomatic benign prostatic hyperplasia (BPH) may 
benefit from surgical treatment of his cancer, which would also alleviate his symptoms of BPH.  
A summary of common interventions for CaP and associated HRQOL side effects is 
listed in Table 1. Because there is limited evidence that any of the treatments for localized 
disease is superior to another in terms of overall survival, patients must consider other variables 
when choosing therapy. One of these other considerations is quality of life (QOL). Recognition 
of the importance of HRQOL related to the side effects of CaP treatments has grown over the 
years. Although the awareness by physicians and patients has increased, there is still a paucity of 
objective data of HRQOL for CaP treatment, primarily due to the relative lack of prospective 
trials. It is critically important that clinicians understand the impact of CaP and its effect on 
HRQOL so that they can better counsel their patients and make early interventions that improve 
patient outcomes. The aim of this review is to briefly establish the definition of HRQOL as well 
as the known consequences of CaP treatments on HRQOL, and review updates on this topic in 
recent literature concerning the management of localized CaP. 
 
Definition and Measurement of HRQOL in CaP 
HRQOL is measured using standardized questionnaires, which collect patient-centric data 
and provide an objective assessment and perception of both generic and disease specific 
domains. In the past, health care providers would document what was perceived QOL, but a 
more accurate measure includes patient-driven perception of personal health, the ability to 
function in life, and overall sense of satisfaction with life experiences [4]. The ultimate goal of 
HRQOL is to detect variation in the natural history of disease and treatment effects not described 
by vital status or observations recorded in the clinical record [5]. There are several validated 
questionnaires, also commonly described as “instruments” or “tools,” developed for patients with 
CaP. 
The University of California Los Angeles Prostate Cancer Index (UCLA-PCI) was the 
first validated questionnaire specifically designed to measure HRQOL in localized CaP patients. 
General HRQOL domains were borrowed from the established Medical Outcomes Study Short 
Form (SF-36), and prostate-specific domains were included: urinary function and bother, sexual 
function and bother, and bowel function and bother. Briefly, the SF-36, which is perhaps the 
most widely used tool for general HRQOL, consists of eight scaled scores: vitality, physical 
functioning, bodily pain, general health perceptions, physical role functioning, emotional role 
functioning, social role functioning, and mental health [5].  
The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument 
designed to evaluate patient function and bother after CaP treatment. Content from the original 
UCLA-PCI was expanded with guidance from a cohort of localized CaP patients and an expert 
panel comprised of urologic oncologists, radiation oncologists, survey researchers, and CaP 
nurses. This extensive panel found a need to augment the UCLA-PCI with items to capture 
additional concerns relevant to BT, RT, RP, and androgen deprivation. Symptom-specific bother 
items corresponding to each symptom item were added to elicit multi-item bother scales for each 
HRQOL domain [4]. 
The European Organization for Research and Treatment of Cancer Core Quality of Life 
Questionnaire (EORTC QLQ-C30) is a 30-item self-reported questionnaire developed to assess 
the QOL of cancer patients. It is grouped into five functional subscales: role, physical, cognitive, 
emotional, and social functioning. In addition, there are three multi-item symptom scales 
(fatigue, pain, and nausea and vomiting), individual questions concerning common symptoms in 
cancer patients, and two questions assessing overall QOL. The EORTC QLQPR25 was 
developed to incorporate an additional 25-item subset specific to CaP [6].  
 
Effect of Patient Treatment Options on Patient QOL 
 
Active Surveillance  
 
CaP can progress slowly and, with or without treatment, a large number of men can live 
many years after diagnosis. The realization that low-risk CaP may sometimes be overtreated by 
surgery or radiation has been an impetus in the development of an active surveillance (AS) 
protocol. Therefore, men with favorable disease-specific features are candidates for AS, and 
perhaps can benefit from the avoidance of various side effects of treatment of localized 
CaP such as incontinence, bleeding, gastrointestinal toxicity, and erectile dysfunction. Although 
physical side effects may be avoided with AS, there is an emerging concern that patients may be 
at an increased risk of psychologic distress. HRQOL was evaluated in 129 men that were 
enrolled in the Prostate Cancer Research International: Active Surveillance (PRIAS) study. 
Although for the most part, AS was well tolerated among the cohort, certain risk factors for 
patients who may not do well on AS emerged. A perception of the physician contributing to the 
majority of the decision making, a poor physical health score, a high neuroticism (anxiety) score, 
and a high PSA value all had significant positive associations with lower HRQOL scores [7]. 
Burnet et al. [8] also noted that AS, as a treatment entity, did not offer higher overall 
psychological distress compared with other CaP treatments, but analyses indicated that higher 
anxiety scores were significantly associated with younger age and a longer time interval from 
diagnosis. In addition, higher depression scores were significantly associated with a longer 
interval since diagnosis (P<0.05), but not with management by AS. Therefore, although AS has 
substantial benefits, it can also have significant effects on QOL, and additional research is 
needed to define how to minimize the specific QOL domains affected.  
The National Cancer Institute (NCI)-endorsed phase III Study of Active Surveillance 
Therapy Against Radical Treatment in Patients Diagnosed With Favorable-Risk Prostate Cancer 
(START) trial, currently enrolling patients in the United States and Canada, will compare the 
disease-specific survival of patients who have favorable risk CaP treated with RP or radical RT 
at the initial diagnosis with that of patients whose treatment is AS and selective active treatment 
intervention (either radiation or surgery). In addition to cancer-related outcomes, the study will 
use a number of QOL instruments to further examine the QOL problems these different 




Several trials have shown that RP has significant negative effect on multiple QOL 
domains such as lower sexual function score, lower urinary function and incontinence scores, 
and lower physical  HRQOL [10, 11••, 12], [13••]. Although certain advances have been made 
that help diminish these side effects, such as nerve sparing prostatectomy (NSP) or robotic-
assisted radical prostatectomy (RARP), their impact on HRQOL still remains controversial.  
Significant controversy exists regarding the outcomes of RARP and open RP. Although 
there are limited published data on HRQOL outcomes specifically to RARP, one can look at 
functional outcomes and deduce the effects on QOL from the open RRP patients. Coelho et al. 
[14] concluded, after evaluating current RARP outcomes, that this technique offers comparable 
functional outcomes to open RRP. Therefore, RARP should theoretically offer similar HRQOL 
scores to open RRP. These outcomes are different than those reported in a recent article by Hu et 
al. [15•], which examined minimally invasive RP (all laparoscopic techniques) and traditional 
open RP. Measured outcomes of incontinence and erectile dysfunction were higher in the 
minimally invasive group compared with the open RP group, using a dataset of nearly 2000 
Medicare patients from the years 2003 to 2007. Among the criticism of the report, the study 
failed to stratify the patients between RARP and laparoscopic RP, for which a more pronounced 
learning curve exists. In addition, the time period (2003– 2007) that was examined was when 
minimally invasive prostatectomy was first becoming popular and more widely available in 
United States, putatively during most surgeons’ initial learning curve. Finally, the study did not 
control hospital and surgeon case volumes, which is known to correlate with outcomes. 
Nevertheless, the data suggested worse functional outcomes in patients undergoing minimally 
invasive RP when compared with open RP.  
Preserving the neurovascular bundles (NSP) reduces the incidence of impotence post 
prostatectomy in both open RP and robotic-assisted RP [11••, 16]. In addition, some studies have 
also suggested that NSP can help improve urinary function. Abel et al. [16] evaluated 91 
consecutive patients divided into two cohorts according to the percentage of nerve sparing 
performed, >50% versus ≤50%, at the time of RP. Nerve sparing was associated with better 
urinary function (P=0.014) and urinary bother (P=0.043). After adjusting for preoperative 
variables, the increased NSP group scored 8.4 points higher for urinary function and 8.5 points 
higher for urinary bother compared with the non- NSP group. Long-term (>5 years) 
improvement in urinary incontinence was seen in the NSP group by Nandipati et al. [17]. 
Urinary continence status was defined as completely pad-free or wearing a single pad for 
protection (dry pad). Overall incontinence rate was reported to be higher in the non-NS than the 
bilateral NS (29.5% vs 9.1%, respectively; P<0.05). Return of incontinence was also 
significantly quicker in the bilateral NS group. Although several anecdotal opinions exist, such 
as a more meticulous apical dissection at the time of NSP and more careful overall technique, the 
exact causal mechanism of NSP in improving urinary function is not known.  
 
Radiotherapy of the Prostate 
Patients undergoing RT for localized CaP can have urinary, sexual, and gastrointestinal 
tract dysfunction after treatment. However, the symptomatology of urinary dysfunction after RT 
is different than that of patients who undergo surgery. Unlike surgery, which can result in stress 
urinary incontinence, RT can result in irritative voiding symptoms, such as urgency, frequency, 
and urge incontinence, that negatively affect overall urinary function and HRQOL. Also, specific 
to RT is a higher incidence bowel irritation. BT and RT were both associated with a reduced 
QOL related to bowel function early after treatment, continuing in some patients for more than a 
year. Sanda et al. [11••] reported rectal urgency, frequency, pain, fecal incontinence, or 
hematochezia-caused distress related to bowel function in 9% of patients a year after RT. The 
most predominant severe acute toxicity after BT is urinary retention requiring catheterization 
[18]. In fact, Roeloffzen et al. [18] reported that acute urinary retention after prostate BT has a 
significant negative impact on patients’ HRQOL up to 6 years after treatment, in terms of both 
global QOL measures and urinary symptom scores. Proper selection of patients can minimize the 
risk of retention following BT. 
Postoperative RT for CaP in a salvage or an adjuvant setting presents a unique challenge, 
in that maximizing urinary continence and potency prior to delivery of RT is of concern. 
Pinkawa et al. [19] evaluated 101 patients prospectively that received RT for positive surgical 
margins and/or persisting or rising PSA levels after RP. Median time between RP and beginning 
of RT was 16 months. Function and bother scores at baseline and different time intervals were 
recorded after RT. The time between RP and RT did not correlate with a significant difference in 
function scores. RT-associated sexual toxicity played a minor role in this study because only 7% 
of patients reported erections firm enough for intercourse. HRQOL scores in the urinary and 
bowel domains decreased significantly in the acute phase. Urinary scores recovered rapidly 
within the first weeks after RT. On the other hand, bowel scores remained significantly lower for 
a longer period of time, and only recovered back to baseline 1 year after RT. Twenty-nine 
patients received a course of androgen deprivation for a median duration of 9 months prior to 
RT. HRQOL scores in this subgroup decreased in the hormonal domain but returned back to 
baseline 1 year after RT. 
Androgen deprivation therapy is well known to have a significant impact on hormonal 
HRQOL domain. Symptoms in this category include hot flashes, gynecomastia, lack of energy, 
weight gain, bone loss, increased risk of metabolic syndrome, and depressive mood changes. 
These concerns are increasingly relevant in the measurement of consequences from localized 
CaP treatment because the use of neoadjuvant and adjuvant hormonal therapy has become more 
common with RT. Neoadjuvant hormonal therapy can also be used for cytoreduction for patients 
with large prostates, to make them eligible for BT or surgical intervention. Side effects of 
androgen deprivation in localized disease must be discussed with patients, as their administration 
can have a significant and long-lasting impact on the QOL of patients.  
 
Physician Awareness of HRQOL 
Increased awareness of the impact of cancer on HRQOL of patients and accurate study of 
HRQOL have been slow to permeate the field of urologic oncology. A study by Sonn et al. [20•] 
examined the frequency of various impairment factors, such fatigue, pain, and sexual, urinary, 
and bowel dysfunction who had undergone RP, BT, or External beam radiation therapy recorded 
by the physician and those self-reported by the patient. The authors compared a modern cohort of 
a period from 2000 to 2007 with that from 1995 to 2000. Participants independently completed 
the SF-36 and the UCLA-PCI. Urologists noted impairment in urinary and sexual function more 
accurately than fatigue or pain. Disagreement between physician and participant ratings did not 
vary dramatically from short-term to long-term follow-up, or from the earlier to the later cohort, 
indicating, despite the increased awareness in literature, a need for further provider awareness on 
QOL issues. As the time from primary treatment increased, patients did report less impairment in 
all domains, but physicians recorded more improvement than did their patients. This study 
clearly shows that the wide gap continues to exist between the HRQOL that patients report and 
that which their physicians assess.  
 
Impact of Screening and Diagnosis on HRQOL 
PSA screening and monitoring can adversely affect patients’ anxiety levels and therefore 
have a diminutive effect on their QOL. Even prior to being diagnosed with CaP, there can be 
mental anguish and anxiety resulting in a decreased QOL from CaP screening. Carlsson et al. 
[21] evaluated the anxiety levels of nearly 1800 men with PSA ≥3 ng/mL partaking in the 
European Randomized Study of Screening for Prostate Cancer. The study illustrated that most 
men have low to moderate anxiety while waiting for further clinical examination for an elevated 
PSA, and that <5% of men reported high levels of anxiety. Despite the high sensitivity of PSA, 
variable factors can falsely elevate PSA, including benign enlargement of the prostate. Katz et al. 
[22] evaluated the effect on psychological well-being of 109 men with an abnormal PSA test or 
an abnormal digital rectal examination (DRE) but a negative biopsy result. Men with abnormal 
CaP screening tests report increased cancer related worry and more problems with sexual 
function, despite having a negative biopsy result. Therefore, false positive results may contribute 
to a significant decrease in QOL, stressing the point that effective counseling is recommended 
before CaP screening and during follow-up.  
Increased anxiety is common after being diagnosed with CaP. Understanding the specific 
domains of well-being affected by the diagnosis can help urologists mediate the negative effects 
[5]. Love et al. [23] conducted a prospective QOL evaluation of 367 men newly diagnosed with 
either early or advanced CaP compared with a CaP-free, age-matched comparison group of men. 
The diagnosis of CaP had a significant, negative effect on vitality, social functioning, role 
emotional, and mental status, as measured by the SF-36. Additionally, a greater rate of  anxiety 
was seen in men diagnosed with early-stage (5.2%) and advanced-stage (5.8%) CaP compared 
with aged-matched controls. Strategies that may introduce early recognition and intervention 
may perhaps slow the deterioration or even improve the patient’s QOL, while the patient is going 
through a treatment process. The elderly population in the United States is no exception. A 
longitudinal population based study by Reeve et al. [24] examined the impact a diagnosis of CaP 
has on HRQOL in the aging population. Patients that were newly diagnosed with prostate cancer 
experienced statistical declines in physical health (mean score decline of 3.4) and significant 
decreases in mental health (mean score decline of 2.8) relative to the mean change of the control 
subjects.  
This also illustrates the importance for urologists to understand the impact of CaP and its 
treatment on QOL so that patients can be better counseled on expectations and that care 
providers can provide early interventions for certain QOL domains.  
 
 
Preoperative Tumor Characteristics Effect on HRQOL 
 
Are there certain tumor parameters that help predict which patients with CaP will do 
better than their counterparts? Gacci et al. [25] retrospectively reviewed 595 patients who had 
undergone either RP or RT. Significantly better urinary function and bother scores were noted in 
patients with localized, low-risk CaP (cT1-2, Gleason score ≤3 + 3, and PSA ≤10 ng/mL). 
Moreover, men with low clinical stage, low Gleason score, and low preoperative PSA had 
significantly better sexual function scores. Interestingly, there was not a statistical difference in 
sexual bother scores in the higher risk patients, perhaps reflecting better preoperative counseling 
and posttreatment expectations of sexual recovery. Moreover, biochemical recurrence also 
influenced urinary function and bother, as well as sexual function and bother, perhaps reflective 
of a general decrease in QOL after discovery of cancer recurrence.  
 
HRQOL and Survival 
 
It has been shown that a higher HRQOL, after controlling from clinical and demographic 
variables, can improve survival in several types of malignancies, including breast cancer [26]. 
Aside from a better QOL, is there a similar impact in survival in patients diagnosed with CaP by 
merely improving QOL? Sadetsky et al. [27] examined this issue in a recent article, in which 
they evaluated patients from the CaPSURE database. HRQOL and survival in patients with CaP 
were evaluated after controlling for age at diagnosis, type of treatment received, clinical risk 
classification, and number of comorbidities. Higher levels of physical function and general 
health were significantly associated with better survival (HR, 0.49; 95% CI, 0.32– 0.78, and HR 
0.51, 95% CI, 0.35–0.75, respectively). It is not clear if there is a direct causal relationship 
between HRQOL and survival from CaP, but perhaps this association could provide the stimulus 
to investigate and provide a link between a patient’s perception and the severity of the 
underlying disease.  
 
Spousal Effect on HQROL 
Patients with CaP often rely exclusively on their spouses for support, and therefore, the 
role as a primary caregiver can be stressful for spouses. Despite the high prevalence of prostate 
cancer, little information is available on the QOL of men and their spouses during the phases of 
diagnosis and treatment of CaP. Northouse et al. [28] evaluated patients with CaP and their 
spouses through a comprehensive psychosocial assessment across three phases of illness: new 
diagnosis, biochemical recurrence, and advanced CaP. Spouses’ risk for distress scores did not 
differ from patients’ scores, indicating that spouses are not immune to the effects of illness. In 
fact, spouses had a greater need for the intervention than patients.  
Decreases in the QOL from CaP treatment can extend to a patient’s spouse or partner. 
This was shown by Sanda et al. [11••], in which significant distress in the spouse was reported 1 
year after initial treatment. As one would expect, the spousal group with the highest erectile 
dysfunction related distress was reported by 44% of partners in the RP group, 22% in the RT 
group, and only 13% in the BT group. Obviously, it must be noted that the RP patient group had 
higher baseline sexual scores and experienced the greatest decrease in QOL score, which is 
reflected in the spouse group. In addition, the RP group was younger and with less comorbidities 
and perhaps enjoying a more meaningful sexual life, which is precipitously affected immediately 
after surgery. Patients’ reported bowel and urinary symptoms associated with spousal distress 
were lower and ranged from 3% to 7% in all three groups. Finally, the level of spousal distress 
arising from a patient’s sexual and urinary symptoms after primary CaP treatment was also 
associated with the partner’s level of satisfaction with the treatment outcome in multivariate 
analysis.  
Clearly, a health care provider should also include the patient’s partner when deciding the 
appropriate intervention for CaP. Similar to other studies, Badr and Taylor [29] reported that 
within couples, patients’ and their partners’ sexual function and satisfaction were very similar. 
When patients had poor erectile function, their partners were more likely to report that the couple 
avoided open spousal discussions; this in turn was associated with partners’ marital distress. 
Patients and partners who reported high levels of mutual constructive communication also 
reported greater marital adjustment, regardless of their own sexual satisfaction. The authors of 
the study concluded that psychosocial interventions that facilitate healthy spousal 
communication and address the sexual rehabilitation needs of patients and their partners after 
CaP treatment is important.  
Several studies have demonstrated that early intervention by the health care provider can 
improve QOL. Although no difference was seen between patient groups on prostate specific 
symptoms, spouses in the intervention group reported higher QOL, more self-efficacy, better 
communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and 
symptom distress lasting up to 12 months compared with controls [30].  
Harden et al. [31] applied the Family Involvement, Optimistic Outlook, Coping 
Effectiveness, Uncertainty Reduction, and Symptom Management (FOCUS) program, which 
was originally developed for women with advanced breast cancer and their family caregivers, to 
prostate cancer patients and partners. Couples identified this as an opportunity to raise difficult 
issues they might not have discussed with their care provider, and reported high satisfaction with 
the program. Spouse participation in a supportive, educative intervention increased 
communication with their husbands, lessened their uncertainty, and reduced their negative 
appraisal of caregiving. Unique to CaP patients is that the vast majority of partners are women 
(99% in this study). Partners in this study reported more satisfaction overall than caregivers of 
breast cancer patients (64% were husbands). These differences may be related to the more active 
caregiving or illness management role that female spouses versus the supportive role caregivers 
(primarily husbands) of breast cancer patients assume. 
 
HRQOL in Minority Populations 
Controlling for variables, does the black population experience similar QOL compared 
with the white population undergoing CaP treatment? Jayadevappa et al. [32] conducted a 
prospective study evaluating QOL and satisfaction with care after RP or RT. Compared with 
white patients, black patients were less likely to choose RP as primary treatment, although when 
statistically controlled, ethnicity was not associated with treatment type in statistical significance. 
Baseline prostate QOL scores were similar in both groups, except the black group reported 
higher pains in back, legs, or hips. There were a higher percentage of black men accrued from 
the Veterans Administration (68% vs 42%). It is unclear that this difference serves as a 
discrepancy in the consistency of are delivered between the two groups. The majority of white 
men were college educated, married, and had an annual income of >$40,000 (63% vs 22% in the 
black population). Outcomes of this study included the following: black men took a longer time 
to return to their baseline generic and sexual bother HRQOL scores; and black men reported 
poorer outcomes by 12 months for some generic and prostate-specific HRQOL domains, 
including lower 12- month scores on role physical, role emotional, bodily pain, urinary function, 
and urinary bother. The etiologies of these discrepancies are unknown, but perhaps it is because 
black patients express lower physician trust than their white counterparts [33]. Alternatively, 
black patients may have lower satisfaction rates with the services they receive. Regardless, this 
highlights the need for further research to help health care providers to be effective in improving 
and reducing variations in outcomes seen in the racial minority  population. 
 
Conclusions 
One of the most useful papers on HRQOL in CaP was published by Sanda and associates 
[11••]. This prospective study of more than 1,200 patients and 625 spouses or partners serves as 
a landmark paper in the field and should be standard reading for any provider who counsels 
patients with localized prostate cancer.  
QOL is affected in both the short- and long-term for men treated for CaP. QOL issues are 
important for treating physicians to be familiar with and understand as we strive to provide 
optimum care to these men and their families along the often lengthy period of the disease 
trajectory. A considerable impact on the QOL of patients’ families is associated with definitive 
treatment. The mere diagnosis of CaP and AS strategies can also negatively affect patients’ 
QOL. Therefore, the patient, spouse or partner, and physician all need to carefully consider, not 
only the efficacy, but also the  consequences of each treatment option, including the potential 
adverse effects and effect on QOL. Investigations of all new and existing therapies should 
attempt to gather prospective and objective data on HRQOL. 
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 Treatment Modality HRQOL Side Effects 
AS Greater level of depression [8] 
Higher anxiety score [7] 
RP Greater level of depression [33] 
Lower sexual function score [10,11••,12] 
Lower urinary function score [10,11••,12] 
Lower urinary incontinence score, but improved urinary 
irritation or obstruction symptoms [11••] 
EBRT Greater level of depression [33] 
Lower sexual function score, worsened with ADT [11••] 
Lower bowel function score [11••] 
Lower physical HR-QOL, worsened with ADT [11••] 
BT Greater level of depression [33] 
Lower urinary irritation or obstruction scores [11••,17] 
Lower bowel function score [11••] 
 
